Literature DB >> 24850760

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

Regina Jitschin1, Martina Braun1, Maike Büttner2, Katja Dettmer-Wilde3, Juliane Bricks1, Jana Berger1, Michael J Eckart4, Stefan W Krause1, Peter J Oefner3, Katarina Le Blanc5, Andreas Mackensen1, Dimitrios Mougiakakos1.   

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population that shares certain characteristics including an aberrant myeloid phenotype and the ability to suppress T cells. MDSCs have been predominantly studied in malignant diseases and findings suggest involvement in tumor-associated immune suppression. Chronic lymphocytic leukemia (CLL) is the leukemia with the highest incidence among adults. Immune defects occur already at early disease stages and impact the clinical course. We assessed presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression (HLA-DR(lo)) in patients with untreated CLL. These monocytic cells represent one of the best-defined human MDSC subsets. Frequency of CD14(+)HLA-DR(lo) cells was significantly increased in CLL patients. Furthermore, MDSCs suppressed in vitro T-cell activation and induced suppressive regulatory T cells (TRegs). The MDSC-mediated modulation of T cells could be attributed to their increased indoleamine 2,3-dioxygenase (IDO) activity. CLL cells induced IDO(hi) MDSCs from healthy donor monocytes suggesting bidirectional crosstalk between CLL-cells, MDSCs, and TRegs. Overall, we identified a MDSC population that expands in CLL. The exact mechanisms responsible for such accumulation remain to be elucidated and it will be of interest to test whether antagonizing suppressive functions of CLL MDSCs could represent a mean for enhancing immune responses.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850760     DOI: 10.1182/blood-2013-12-546416

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  113 in total

1.  Ibrutinib treatment improves T cell number and function in CLL patients.

Authors:  Meixiao Long; Kyle Beckwith; Priscilla Do; Bethany L Mundy; Amber Gordon; Amy M Lehman; Kami J Maddocks; Carolyn Cheney; Jeffrey A Jones; Joseph M Flynn; Leslie A Andritsos; Farrukh Awan; Joseph A Fraietta; Carl H June; Marcela V Maus; Jennifer A Woyach; Michael A Caligiuri; Amy J Johnson; Natarajan Muthusamy; John C Byrd
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

2.  Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.

Authors:  Naureen Javeed; Michael P Gustafson; Shamit K Dutta; Yi Lin; William R Bamlet; Ann L Oberg; Gloria M Petersen; Suresh T Chari; Allan B Dietz; Debabrata Mukhopadhyay
Journal:  Oncoimmunology       Date:  2016-11-02       Impact factor: 8.110

3.  PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Authors:  Bola S Hanna; Philipp M Roessner; Annika Scheffold; Billy M C Jebaraj; Yasmin Demerdash; Selcen Öztürk; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

4.  Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.

Authors:  Chih-Hang Tang; Shiun Chang; Ayumi Hashimoto; Yi-Ju Chen; Chang Won Kang; Anthony R Mato; Juan R Del Valle; Dmitry I Gabrilovich; Chih-Chi Hu
Journal:  Cancer Immunol Res       Date:  2018-04-12       Impact factor: 11.151

Review 5.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

6.  CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D.

Authors:  H Bruns; M Böttcher; M Qorraj; M Fabri; S Jitschin; J Dindorf; L Busch; R Jitschin; A Mackensen; D Mougiakakos
Journal:  Leukemia       Date:  2016-12-23       Impact factor: 11.528

Review 7.  CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors:  Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

8.  Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals.

Authors:  Ling Wang; Juan Zhao; Jun P Ren; Xiao Y Wu; Zheng D Morrison; Mohamed A Elgazzar; Shun B Ning; Jonathan P Moorman; Zhi Q Yao
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

Review 9.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.